AVIR Stock: Earnings, Dividends & Analyst Estimates

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $2.78 - $6.45

5.9 Year AVIR Performance Metrics:

Total Return (with DRIP): -82.8% (-25.82% CAGR)

Total Return (no DRIP): -82.8% (-25.82% CAGR)

Share Price: -82.8% (-25.82% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $1,717

Total Return $ (with DRIP): -$8,283

AVIR Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

AVIR Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for AVIR

Based on past 5.9-year performance, here are AVIR growth metrics:

Share price CAGR of -25.82%
Dividend CAGR of +0%

Using AVIR CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	AVIR (DRIP)	AVIR - No DRIP
Current Price	$5.21	$5.21
Start Shares	1,919.39	1,919.39
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	1,919.39	1,919.39
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.26	$5.21
Total Dividends	$0	$0
Final Value	$505	$10,000

Estimated Future Value + Dividends - AVIR

NOTE: Above numbers are our estimate based on AVIR's Dividend and Price CAGR over past 5.9 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Atea Pharmaceuticals, Inc. (AVIR) had its IPO on , and is traded on NASDAQ stock exchange.

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral infections. Atea Pharmaceuticals’ current programs center on treatments for hepatitis C, including a late-stage regimen combining bemnifosbuvir and ruzasvir, as well as broader antiviral research across other RNA virus targets. The company also works on therapies for hepatitis E and other viral diseases, reflecting its emphasis on unmet medical needs in infectious disease. Its portfolio is designed around small-molecule oral medicines, which are intended to support convenient outpatient treatment options and address diseases that can require long-term or difficult-to-administer care. Based in Boston, Massachusetts, Atea Pharmaceuticals operates in the biopharmaceutical sector, where antiviral drug development plays a significant role in advancing treatment choices for patients and healthcare providers.

AVIR website: https://ateapharma.com